Skip to main content
OpenTrials
Completed

NCT Number: NCT02860793

Role of PTK-7 in Acute Myeloid Leukemias

The pseudo tyrosine kinase receptor 7 (PTK7) is an orphan tyrosine kinase receptor assigned to the planar cell polarity pathway. PTK7 is expressed in normal myeloid progenitors and CD34(+) CD38(-) bone marrow cells in humans. It is also expressed in acute myeloid leukemia (AML) and is mostly assigned to granulocytic lineage differentiation. In AML, PTK7 seems to convey promigratory and antiapoptotic signals into the cell and represents an independent prognosis factor of survival in patients treated with induction chemotherapy. This study aims at:

* evaluating the impact of PTK7 expression on primary AML cells ex vivo * evaluating the diagnostic and prognostic value of a soluble form of PTK7

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Myeloid Leukemia Hematologic Diseases Hemic and Lymphatic Diseases Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Neoplasms Neoplasms by Histologic Type

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Institut Paoli Calmettes

Marseille, Bouches du Rhone, 13009, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age> 18 years
  • AML at diagnosis, not previously treated
  • Treatment by induction chemotherapy
  • Signed informed consent
  • Affiliation to the French social security system

Exclusion criteria

  • pregnant woman(or of childbearing potential) or breastfeeding woman
  • emergency
  • patients deprived of liberty or placed under the authority of a tutor

Treatment and study plan

Bone Marrow aspiration

Other

Blood sampling

Other

Primary outcomes

  1. Evaluation PTK7+ and PTK7- AML cells hematopoietic homing abilities in xenografted mice by in vivo bioluminescence imaging

    Time frame: 1 day

  2. Soluble PTK7 measurement in the serum

    Time frame: 12 years

Sponsors and collaborators

Lead sponsor

Institut Paoli-Calmettes

Other

Registry information

Official study title

Role of PTK-7 in Acute Myeloid Leukemias: Impact of PTK7 Serum Marker and ex Vivo Studies to Decipher the Role of PTK7

Acronym: LAM-PTK7

Important dates

Study start
2014
Primary completion
2015
First posted
Aug 9, 2016
Registry last updated
Aug 10, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.